Dr. Charles Theuer is Chief Medical Officer of Halozyme. He previously led TRACON Pharmaceuticals as President and CEO from 2006. At Pfizer he led clinical development of the kidney-cancer drug Sutent, and at TargeGen he started the program behind Inrebic, now approved for myelofibrosis. A board-certified general surgeon, he holds a BS from MIT, an MD from UCSF and a PhD in Epidemiology from UC Irvine.
Celebrating Health • HEALTHCARE
REIMAGINED
© 2026 TALHospitals HealthFest. All rights reserved.